The role of TILs as prognostic markers, especially CD8 and FOXP3 subtypes, has been evaluated in large studies, the majority focusing on ER−, HER2+, and triple negative breast cancers. The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.